Galderma Group AG (FRA:PY30) Debt-to-Equity : 0.39 (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Debt-to-Equity?

Galderma Group AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €30 Mil. Galderma Group AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €2,707 Mil. Galderma Group AG's Total Stockholders Equity for the quarter that ended in Jun. 2024 was €7,090 Mil. Galderma Group AG's debt to equity for the quarter that ended in Jun. 2024 was 0.39.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Galderma Group AG's Debt-to-Equity or its related term are showing as below:

FRA:PY30' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.39 Med: 0.39 Max: 0.39
Current: 0.39

During the past 0 years, the highest Debt-to-Equity Ratio of Galderma Group AG was 0.39. The lowest was 0.39. And the median was 0.39.

FRA:PY30's Debt-to-Equity is ranked worse than
59.93% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs FRA:PY30: 0.39

Galderma Group AG Debt-to-Equity Historical Data

The historical data trend for Galderma Group AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Debt-to-Equity Chart

Galderma Group AG Annual Data

Trend

Debt-to-Equity

Galderma Group AG Semi-Annual Data
	Jun23	Jun24
Debt-to-Equity	N/A	0.39

Competitive Comparison of Galderma Group AG's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galderma Group AG's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Galderma Group AG's Debt-to-Equity falls into.

Galderma Group AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Galderma Group AG's Debt to Equity Ratio for the fiscal year that ended in . 20 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(	+	)	/	N/A
	=	N/A

Galderma Group AG's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(29.728	+	2707.106)	/	7090.128
	=	0.39

Galderma Group AG (FRA:PY30) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Galderma Group AG Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (FRA:PY30) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GALDY:USA GDERF:USA GALDz:UK GALD:Switzerland

Address

Zahlerweg 10, Zug, CHE, 6300

Website

https://www.galderma.com

Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines